Literature DB >> 4312546

A new method for the measurement of acute alterations in thyroxine deiodination rate in man.

J T Nicoloff.   

Abstract

A newly devised dual labeled iodine isotopic method is described for the detection and quantitation of alterations in thyroxine (T(4)) deiodination rate in man. This method employs the principle of a constant (125)I infusion to serve as a reference source for the generation of (131)I derived from the deiodination of T(4)-(131)I. Measurement of these two iodide isotopes are made in serially timed urine collections and are expressed in terms of a ratio value. Using this technique, it was possible to measure accurately the effects of a single dose of 6-propylthiouracil (6-PTU) in producing inhibition of T(4) deiodination in euthyroid subjects. It was also possible to assess the time of onset, duration of action, and degree of inhibition produced by 6-PTU. Employing single doses of 6-PTU, ranging from 100 to 1000 mg, there was found to be a log dose relationship with a degree of inhibition observed in T(4) deiodination. In control studies T(4) deiodination rate was found to be constant for periods ranging up to 72 hr in normal ambulating subjects. The acute administration of many other agents was employed in an attempt to alter the T(4) deiodination rate. These included diphenylhydantoin, methimazole, triiodothyronine, thyroxine, thyroid stimulating hormone (TSH), adrenocorticotropin (ACTH), hydrocortisone, predinsolone, potassium iodide, epinephrine, and oxytocin. No detectable change in T(4) deiodination rate was observed with these agents in the dosage ranges employed in this study. The lack of any observable alteration in the T(4) deiodination rate in response to this array of drugs and hormones appears to indicate that the availability of T(4) to intracellular sites of deiodination and possibly action is well modulated to resist abrupt changes.

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 4312546      PMCID: PMC322469          DOI: 10.1172/JCI106236

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  34 in total

1.  EFFECTS OF THIOURACIL AND OF THYROIDECTOMY OF LIVER PROTEIN METABOLISM.

Authors:  M B YATVIN; R W WANNEMACHER; W L BANKS
Journal:  Endocrinology       Date:  1964-06       Impact factor: 4.736

2.  EFFECT OF 5- AND 6-PROPYLTHIOURACIL ON THE METABOLISM OF L-THYROXINE IN MAN.

Authors:  J M HERSHMAN
Journal:  J Clin Endocrinol Metab       Date:  1964-02       Impact factor: 5.958

3.  Regulation of the peripheral metabolism of the thyroid hormones.

Authors:  S H INGBAR; N FREINKEL
Journal:  Recent Prog Horm Res       Date:  1960

4.  The mechanism of protein iodination during the metabolism of thyroid hormones by peripheral tissues.

Authors:  V A GALTON; S H INGBAR
Journal:  Endocrinology       Date:  1961-07       Impact factor: 4.736

5.  Depression of the serum protein-bound iodine level by diphenylhydantion.

Authors:  J H OPPENHEIMER; L V FISHER; K M NELSON; J W JAILER
Journal:  J Clin Endocrinol Metab       Date:  1961-03       Impact factor: 5.958

6.  Decreased serum free thyroxine concentration in patients treated with diphenylhydantoin.

Authors:  W Chin; G C Schussler
Journal:  J Clin Endocrinol Metab       Date:  1968-02       Impact factor: 5.958

7.  Effect of exercise on thyroxine degradation in athletes and non-athletes.

Authors:  C H Irvine
Journal:  J Clin Endocrinol Metab       Date:  1968-07       Impact factor: 5.958

8.  Free thyroxine in human serum: simplified measurement with the aid of magnesium precipitation.

Authors:  K Sterling; M A Brenner
Journal:  J Clin Invest       Date:  1966-01       Impact factor: 14.808

9.  Estimation of rapidly exchangeable cellular thyroxine from the plasma disappearance curves of simultaneously administered thyroxine-131-I and albumin-125-I.

Authors:  J H Oppenheimer; G Bernstein; J Hasen
Journal:  J Clin Invest       Date:  1967-05       Impact factor: 14.808

10.  Effect of epinephrine on the peripheral metabolism of thyroxine.

Authors:  M T Hays; D H Solomon
Journal:  J Clin Invest       Date:  1969-06       Impact factor: 14.808

View more
  9 in total

Review 1.  Reawakened interest in type III iodothyronine deiodinase in critical illness and injury.

Authors:  Stephen A Huang; Antonio C Bianco
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2008-01-22

2.  Prevention and management of hyperthyroid storm.

Authors:  B M Dobyns
Journal:  World J Surg       Date:  1978-05       Impact factor: 3.352

3.  Increased sensitivity of thyroid hormone-mediated signaling despite prolonged fasting.

Authors:  Bridget Martinez; Michael Scheibner; José G Soñanez-Organis; John T Jaques; Daniel E Crocker; Rudy M Ortiz
Journal:  Gen Comp Endocrinol       Date:  2017-07-22       Impact factor: 2.822

4.  Alterations in 3,3'5'-triiodothyronine metabolism in response to propylthiouracil, dexamethasone, and thyroxine administration in man.

Authors:  J S LoPresti; A Eigen; E Kaptein; K P Anderson; C A Spencer; J T Nicoloff
Journal:  J Clin Invest       Date:  1989-11       Impact factor: 14.808

5.  Reduction in extrathyroidal triiodothyronine production by propylthiouracil in man.

Authors:  M Saberi; F H Sterling; R D Utiger
Journal:  J Clin Invest       Date:  1975-02       Impact factor: 14.808

6.  Triiodothyronine and thyroxine in hyperthyroidism. Comparison of the acute changes during therapy with antithyroid agents.

Authors:  J Abuid; P R Larsen
Journal:  J Clin Invest       Date:  1974-07       Impact factor: 14.808

7.  Degradation of thyroid hormones by phagocytosing human leukocytes.

Authors:  S J Klebanoff; W L Green
Journal:  J Clin Invest       Date:  1973-01       Impact factor: 14.808

8.  A new method for the measurement of thyroidal iodine release in man.

Authors:  J T Nicoloff
Journal:  J Clin Invest       Date:  1970-10       Impact factor: 14.808

9.  Assessment of thyrotropin-releasing hormone and thyrotropin reserve in man.

Authors:  P A Singer; J T Nicoloff
Journal:  J Clin Invest       Date:  1973-05       Impact factor: 14.808

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.